A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer
Our study shows that anthracycline-taxane regimens were the most commonly prescribed adjuvant chemotherapy options in HER2-negative BC. Women who received ACT had the lowest OS, likely due to their unfavorable pathology.
Authors
- Kelvin Chan (ORCID: https://orcid.org/0000-0002-2501-3057)
- Maureen Trudeau (ORCID: https://orcid.org/0000-0002-0938-4499)
- Andrea Eisen (ORCID: https://orcid.org/0000-0001-8037-9556)
- Danilo Giffoni de Mello Morais Mata (ORCID: https://orcid.org/0000-0001-7375-4346)
- Ines B. Menjak (ORCID: https://orcid.org/0000-0002-4239-0858)
- Rossanna C. Pezo
Institutions
- Western University (CA)
- Sunnybrook Health Science Centre (CA)
- University of Toronto (CA)
- Juravinski Cancer Centre (CA)
- London Health Sciences Centre (CA)
- Health Sciences Centre (CA)
- Hamilton Health Sciences (CA)
Publication Details
- Journal
- Current Oncology
- Published
- 2024-12-25
- DOI
- https://doi.org/10.3390/curroncol32010006
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Care Ontario